P/B
0,8
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
$72.3M
Market Cap • 10/2/2026
2008
(18 years)
Founded
2008
(18 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
723,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,3
EPS
—
Market Cap
Market Cap
72,3M
EV
-13,5M
EV/Revenue
-135
EV/EBITDA
0,4
EV/EBIT
0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-151,5%
Total Yield
-151,5%
Payout
0%
Retained Earnings
-365,3M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
19643%
Capex/Revenue
578%
Capex/D&A
56,1%
Capex/OCF
-2,5%
SBC/OCF
—
% PPE
4,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-46,9%
CAGR Op. Income 5Y
2,5%
CAGR Net Income 5Y
5,9%
CAGR EPS 5Y
-64,9%
CAGR OCF 5Y
-5%
Leverage
N.D./EBITDA
2,5
Debt/Equity
0%
Current Ratio
7,9
Quick Ratio
7,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!